Prostate Cancer

VEGF Levels Signify Disease In Patients With Hormone Refractory Malignancy

Published in Cancer Weekly, September 4th, 2001

by Sonia Nichols, senior medical writer - Plasma levels of vascular endothelial growth factor (VEGF) may signal progression and survival in patients with hormone-refractory prostate cancer (HRPC), a group of cancer specialists report.

High levels of the angiogenic growth factor VEGF has been identified in the blood of patients with different types of cancer. Boston, Massachusetts, Dana-Farber Cancer Institute researchers, in collaboration with investigators at several major U.S. research centers, propose plasma levels of VEGF are a significant indicator for survival in HRPC patients based on their evaluation of several Cancer and Leukemia Group B 9480...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-09-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry